GlassScriptPhysician profile
Ryan M Woodham
NPI 1316023211
$5,237.04
in general payments reported to CMS, 2019-2025
31 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $302 · 2021: $142 · 2022: $643 · 2023: $799 · 2024: $961 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.36 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $862.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $691.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $614.36 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $536.95 | 2022-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $406.03 | 2019-2025 | Lifevest |
| Amgen INC. | $330.49 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.72 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $283.67 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $165.77 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $153.14 | 2019-2025 | Watchman Flx, Watchman Access System |
| Biotronik INC. | $127.35 | 2023-2024 | Biomonitor, Rivacor 7 Dr-T, Renamic Neo |
| Amarin Pharma, INC. | $115.83 | 2019-2020 | |
| Abbott Laboratories | $86.23 | 2024-2025 | Ensite, Jot Dx |
| Esperion Therapeutics, INC. | $75.91 | 2021-2025 | Nexletol |
| Gilead Sciences, INC. | $73.88 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $64.79 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $47.78 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.85 | 2019 | |
| Astellas Pharma US INC | $30.54 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $23.87 | 2024 | Nuplazid |
| Kiniksa Pharmaceuticals International, Plc | $21.04 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $20.41 | 2024 | Edarbyclor |
| Actelion Pharmaceuticals US, INC. | $20.13 | 2025 | Opsumit |
| Alnylam Pharmaceuticals INC. | $19.77 | 2019 | |
| Baxter Healthcare | $16.69 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Medtronic, INC. | $16.65 | 2023 | Linq II |
| Bardy Diagnostics, INC. | $16.32 | 2019-2021 | |
| Bracco Diagnostics INC. | $15.75 | 2019 | |
| Itamar Medical INC | $14.07 | 2023 | Watchpatone |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2022 | |
| Edwards Lifesciences Corporation | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Woodham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.